{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:48:29Z","timestamp":1779392909343,"version":"3.53.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ygyno.2020.09.049","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T16:35:46Z","timestamp":1601656546000},"page":"601-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Endocrine therapy in the management of low-grade serous ovarian\/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors"],"prefix":"10.1016","volume":"159","author":[{"given":"David M.","family":"Gershenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren P.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.09.049_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2020.09.049_bb0010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.09.049_bb0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"suppl_5","key":"10.1016\/j.ygyno.2020.09.049_bb0025","first-page":"v851","article-title":"A randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","volume":"30","author":"Gershenson","year":"2019","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.09.049_bb0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.09.049_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/14737140.2017.1272414","article-title":"Endocrine therapy in epithelial ovarian cancer","volume":"17","author":"Langdon","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0040","first-page":"1","article-title":"Tamoxifen for relapse of ovarian cancer (review)","volume":"3","author":"Williams","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","article-title":"A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","volume":"113","author":"Argenta","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.1989.7.1.115","article-title":"Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer","volume":"7","author":"Kavanagh","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0055","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1\u201398 randomised clinical trial at 8.1 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0060","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials","volume":"386","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007695","article-title":"Breast cancer in young women: poor survival despite intensive treatment","volume":"4","author":"Fredholm","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.09.049_bb0070","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/annonc\/mdq072","article-title":"Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer","volume":"21","author":"Cancello","year":"2010","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2020.09.049_bb0075","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12916-015-0472-7","article-title":"Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes\u2014what does it all mean?","volume":"13","author":"Earl","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0110","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0115","first-page":"1","article-title":"Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)","volume":"10","author":"Feng","year":"2017","journal-title":"J. Ovar. Res."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2017.02.029","article-title":"Hormone receptor expression profile of low-grade serous ovarian cancers","volume":"145","author":"Buttarelli","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.humpath.2018.10.020","article-title":"Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network","volume":"85","author":"Sehouli","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2020.09.049_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Llaurado Fernandez","year":"2020","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:53:02Z","timestamp":1758772382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820339597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0090825820339597"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.049","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine therapy in the management of low-grade serous ovarian\/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}